Lupin 2023

PCMA issues statement on HHS report on Rx drug rebates

Print Friendly, PDF & Email

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott issued the following statement on the Health and Human Services Officer of Inspector General report (OIG) on prescription drug rebates in Medicare Part D.

JC Scott

“Today’s OIG report further dispels the false narrative about PBM-negotiated rebates and confirms that rebates lead to lower prescription drug costs in the Medicare prescription drug program. Drug manufacturers alone set and raise drug prices. As the only check on manufacturers’ pricing power, PBMs have been able to achieve an overall stable cost trend for prescription drugs.

OIG’s report adds to a growing body of evidence that the PBM-negotiated rebates lower prescription drug costs. A recent GAO report highlights that virtually all of prescription drug rebates negotiated by PBMs with drug manufacturers in Part D are passed through to drug plan sponsors and used to lower costs for Medicare beneficiaries.

We understand that for some people prescription drug costs remain unaffordable. PBMs will continue working with policymakers to advance solutions that encourage greater competition to reduce drug costs for every consumer.”

Key findings in the OIG report include:

  • Only a small fraction of drugs — 10% — accounted for 60 percent of rebate growth between 2011 and 2015.
  • Rebates did not go up with increases in total reimbursement: 39.3 percent of rebated brand drugs had reimbursement increases and rebate decreases, while 56.3% of rebated brand drugs had reimbursement increases and rebate increases.
  • In Part D on brand drugs with rebates, total reimbursement increased 19 percent, while rebate-adjusted reimbursement increased just 4 percent.


Comments are closed.